Free Trial
→ June 12: Elon Musk’s “Day-One Retirement Plan.” (From Brownstone Research) (Ad)tc pixel
NASDAQ:CING

Cingulate Q4 2025 Earnings Report

Cingulate logo
$4.92 +0.45 (+10.07%)
As of 11:32 AM Eastern
ProfileEarnings HistoryForecast

Cingulate EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q4 2025
Date
3/18/2026
Time
Before Market Opens
Conference Call Date
Wednesday, March 18, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Cingulate's Q4 2025 Press ReleasePress Release
(8-K)
Cingulate's Q4 2025 Annual reportAnnual report
(10-K)

Cingulate Earnings Headlines

Cingulate Reshapes Board Structure and Leadership Roles
May 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cingulate-reshapes-board-structure-and-leadership-roles?utm_source=marketbeat.com&utm_medium=referral
CING: Building its cash position
May 19, 2026  |  msn.comhttps://www.msn.com/en-us/money/economy/cing-building-its-cash-position/ar-AA23zE3d
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
May 26 at 1:00 AM  |  Porter & Company (Ad)
Cingulate (NASDAQ:CING) Lowered to Strong Sell Rating by Wall Street Zen
May 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30780620
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294884/0/en/cingulate-inc-reports-first-quarter-2026-financial-results-and-provides-an-update-of-commercial-readiness-efforts-on-track-for-lead-adhd-asset-ctx-1301.html
10 Best NASDAQ Growth Stocks to Buy and Hold Forever
April 24, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/10-best-nasdaq-growth-stocks-to-buy-and-hold-forever-1743857/
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile
Earnings Tools